首页> 外文OA文献 >Estimating the scale of COVID-19 Epidemic in the United States: Simulations Based on Air Traffic directly from Wuhan, China
【2h】

Estimating the scale of COVID-19 Epidemic in the United States: Simulations Based on Air Traffic directly from Wuhan, China

机译:估计COVID-19疫情的规模在美国:模拟基于空中交通直接从武汉,中国

摘要

Introduction: Coronavirus Disease 2019 (COVID-19) infection has been characterized by rapid spread and unusually large case clusters. It is important to have an estimate of the current state of COVID-19 epidemic in the U.S. to develop informed public health strategies. Methods: We estimated the potential scale of the COVID-19 epidemic (as of 03/01/2020) in the U.S. from cases imported directly from Wuhan area. We used simulations based on transmission dynamics parameters estimated from previous studies and air traffic data from Wuhan to the U.S and deliberately built our model based on conservative assumptions. Detection and quarantine of individual COVID-19 cases in the U.S before 03/01/2020 were also taken into account. We. A SEIR model was used to simulate the growth of the number of infected individuals in Wuhan area and in the U.S. Results: With the most likely model, we estimated that there would be 9,484 infected cases (90%CI 2,054-24,241) as of 03/01/2020 if no intervention procedure had been taken to reduce the transmissibility in unidentified cases. Assuming current preventive procedures have reduced 25% of the transmissibility in unidentified cases, the number of infected cases would be 1,043 (90%CI 107-2,474). Conclusion: Our research indicates that, as of 03/01/2020., it is likely that there are already thousands of individuals in the US infected with SARS-CoV-2. Our model is dynamic and is available to the research community to further evaluate as the situation becomes clearer.### Competing Interest StatementThe authors have declared no competing interest.### Funding StatementCurrent research was supported by NIH, Helmsley Trust and F. Widjaja Foundation.### Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data used in this manuscript are from public source.

著录项

  • 作者单位

    IBIRI institute, Cedars-Sinai Medical Center;Department of Epidemiology and Biostatistics, Peking University Health Science Center;IBIRI Institute, Cedars-Sinai Medical Center;IBIRI Institute, Cedars-Sinai Medical Center;Department of Epidemiology and Biostatistics, Peking University Health Science Center;Department of Epidemiology and Biostatistics, Peking University Health Science Center;IBIRI Institute, Cedars-Sinai Medical Center;;

  • 年度 2020
  • 总页数 14
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 医药、卫生;

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号